Loading clinical trials...

Trip HF Study: Triple Resynchronization in Paced Heeart Failure Patients | Clinical Trials | Clareo Health

COMPLETEDNA

Trip HF Study: Triple Resynchronization in Paced Heeart Failure Patients

Triple Resynchronization in Paced Heart Failure Patients

NCT00187265•Abbott Medical Devices

Summary

The purpose of this study is to evaluate the feasibility of permanent biventricular pacing using three ventricular leads, and its efficacy in terms of inter and intra-ventricular resynchronization, in patients with congestive heart failure and a non-functional atrium (chronic AF).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•NYHA class III-IV congestive heart failure, in spite of optimal medical treatment for their congestive heart failure for 1 month.
•The medical treatment must include a 40 mg/day minimum dose of furosemide (or equivalent);
•Permanent atrial fibrillation (AF);
•Left ventricular ejection fraction (LVEF) ≤ 35%;
•Indication for a pacemaker implantation for a permanent and symptomatic bradycardia, or already implanted pacemaker under the condition that leads positioning corresponds to the criteria described in the protocol;
•Aortic pre-ejection delay at least equal to 140 ms.

Exclusion Criteria

•Indication for a cardiac defibrillator;
•Having presented a myocardial infarct within the previous 3 months;
•Having undergone cardiac surgery or coronary revascularization procedure within the previous 3 months, or being scheduled for such procedures;
•Presenting chronic pulmonary insufficiency;
•Patients whose congestive heart failure requires the use of an intravenous inotropic support;
•Presenting a dysthyreosis;
•Having a life expectancy of less than one year, for other reasons than the congestive heart failure;
•Unable to be followed-up in the scope of the study for geographical reasons;
•Having refused to give their consent;
•Minors (age \< 18 years) and pregnant women.

Locations (1)

Department of Cardiology - CHU Pontchaillou

Rennes, France

Key Dates

Start Date

April 1, 2003

Completion Date

October 1, 2005

Last Updated

February 4, 2019

Conditions

Heart FailureVentricular Dyssynchrony

Interventions

Cardiac Resynchronization Therapy

DEVICE

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

RECRUITINGNA

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Trip HF Study: Triple Resynchronization in Paced Heeart Failure Patients

Inclusion Criteria

Exclusion Criteria

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Assessment of Physical Activity and Cardiovascular Outcomes in Patients With Chronic Heart Failure